MicroVision, Inc. (NASDAQ:MVIS) has been quietly churning out high tech imaging and laser scanning technology for years. But MVIS stock began to soar last fall on news it was developing a lidar system for the automotive sector.
Between the start of December 2020 and Feb. 16 of this year, MVIS stock rocketed up by more than 920%. After a quick correction, it’s surged several times since, hitting a decade-long high close of $26.44 on April 26.
Top 5 High Tech Stocks To Buy Right Now: Ampco-Pittsburgh Corporation(AP)
Ampco-Pittsburgh Corporation and its subsidiaries manufacture and sell custom-engineered equipment in the United States and internationally. It operates in two segments, Forged and Cast Rolls, and Air and Liquid Processing. The Forged and Cast Rolls segment produces forged hardened steel rolls used in cold rolling for the producers of steel, aluminum, and other metals; and cast iron and steel rolls for hot and cold strip mills, medium/heavy section mills, and plate mills. The Air and Liquid Processing segment manufactures finned tube and plate finned heat exchange coils for the commercial and industrial construction, as well as for process and utility industries; custom air handling systems used in commercial, institutional, and industrial buildings; and a line of centrifugal pumps for the refrigeration, power generation, and marine defense industries. The company was founded in 1929 and is based in Pittsburgh, Pennsylvania.
- [By ]
Stephen Moore and Herman Cain in Washington on Aug. 31, 2016, and June 20, 2014, respectively. (Photo: AP)
Why are critics of Moore and Cain saying they are ill-suited for nonpartisan roles?
- [By ]
The front page of the Jan. 28, 2019, edition of the National Enquirer featuring a story about Amazon founder and CEO Jeff Bezos' divorce. (Photo: AP)
- [By ]
Kraft Heinz disclosed it has received a subpoena from the SEC as part of an investigation into the company's procurement accounting policies. (Photo11: AP)
Top 5 High Tech Stocks To Buy Right Now: CareDx, Inc.(CDNA)
CareDx, Inc., a molecular diagnostics company, focuses on the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients in the United States and internationally. The companys commercialized testing solution includes the AlloMap heart transplant molecular test (AlloMap), a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. It is also developing AlloSure, a next-generation sequencing-based test to detect donor-derived cell-free DNA after transplantation. The company markets its AlloMap solution to healthcare providers through its direct sales force that targets transplant centers and their physicians, coordinators, and nurse practitioners. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.